Stereotaxis Receives European CE Mark Approval for MAGiC™ Ablation Catheter: A Game-Changer in Minimally Invasive Endovascular Interventions
ST. LOUIS, MO – January 27, 2025 – Stereotaxis, Inc. (NYSE: STXS), a global leader in robotically-assisted, wireless magnetic navigation technology for the interventional lab, is thrilled to announce that it has received European CE Mark approval for its innovative MAGiC™ ablation catheter. This approval marks a major milestone for Stereotaxis and the community of physicians who are leading the charge in robotics within the field of electrophysiology.
A New Era in Minimally Invasive Endovascular Interventions
The MAGiC™ ablation catheter, which is designed to enable precise and efficient ablation procedures, is an extension of Stereotaxis’ robotic system, Niobe® ES Magnetic Navigation System. This system has already revolutionized the way complex ablation procedures are performed by providing physicians with unparalleled control and accuracy. With the addition of the MAGiC™ ablation catheter, Stereotaxis is poised to further transform the landscape of interventional medicine.
The Impact on Patients
For patients, this CE Mark approval means access to a more precise and effective ablation procedure. The MAGiC™ ablation catheter is expected to offer several advantages over traditional ablation methods, such as:
- Reduced procedure time
- Improved procedural efficacy
- Minimally invasive procedure
- Reduced risk of complications
The Impact on the Medical Community
The European CE Mark approval of the MAGiC™ ablation catheter is a testament to Stereotaxis’ commitment to advancing significant innovations in the field of interventional medicine. This approval is expected to:
- Encourage more physicians to adopt robotics in their practices
- Lead to increased collaboration between robotics and electrophysiology specialists
- Foster a culture of continuous innovation and improvement in the field
A Bright Future for Stereotaxis and Robotics in Interventional Medicine
Stereotaxis’ achievements in robotics and magnetic navigation technology have set the stage for a new era in interventional medicine. With the European CE Mark approval of the MAGiC™ ablation catheter, the company is well on its way to making robotics increasingly impactful across various medical specialties. As the global leader in this field, Stereotaxis remains committed to empowering physicians with advanced technologies that can improve patient outcomes and transform the way procedures are performed.
We are proud to be part of this exciting journey and look forward to the continued advancements that Stereotaxis and the medical community will bring to the world of interventional medicine.
Conclusion
Stereotaxis’ European CE Mark approval for the MAGiC™ ablation catheter represents a significant milestone in the company’s mission to advance robotics in interventional medicine. This approval is expected to lead to improved patient outcomes, increased collaboration among specialists, and a culture of continuous innovation. As the global leader in robotically-assisted, wireless magnetic navigation technology, Stereotaxis continues to push the boundaries of what is possible in the field.
For more information about Stereotaxis and its innovative technologies, please visit www.stereotaxis.com.
